The “Türkiye Pharmaceutical Sector Report 2025” offering a comprehensive overview into the Turkish pharmaceutical sector has been published
06.01.2026
Prepared with contributions from AIFD and EFPIA, the Türkiye Pharmaceutical Sector Report 2025 provides important data ranging from the size of the Turkish pharmaceutical sector, its role in the global pharmaceutical market, pharmaceutical expenditures and R&D potential for researchers and industry stakeholders.
Penned for the third time by IQVIA with support from AIFD (Association of Research-Based Pharmaceutical Companies) and EFPIA, the “Türkiye Pharmaceutical Sector Report 2025” has been published. The third edition of the report examines the Turkish pharmaceutical sector in relation to global trends and similar countries, offering a comprehensive 2025 outlook for the health and pharmaceutical ecosystems.
Prepared annually, the Türkiye Pharmaceutical Sector Report contains current and objective analyses covering a broad spectrum of topics ranging from the overall outlook of the global pharmaceutical market to healthcare expenditures, reimbursement processes, and the core components of the pharmaceutical value chain, namely production, investment, and R&D activities. Thanks to this focus, the report serves as an important reference source for healthcare sector stakeholders and the academic world.
Offering a comprehensive look into the Turkish pharmaceutical industry
The regularly published report series aims to provide information and contribute to a proper understanding of the sector’s current state, and to establish a reliable foundation for decision-makers and researchers. Through international comparisons and long-term trend analyses, it offers a more comprehensive assessment of the different components of the health ecosystem.
Assessing the report, AIFD Secretary General Dr. Ümit Dereli shared: “The Türkiye Pharmaceutical Sector Report 2025 brings together research, analysis, and comparisons related to both the Turkish and global pharmaceutical sectors from an independent perspective. Through this blend, the report serves as an important resource for understanding the current state of the sector and establishing a solid foundation for future work. We place utmost importance in ensuring that these regularly published resources can be used as a reference point by all stakeholders creating value in the healthcare system. As AIFD, we continue to contribute to the accurate and data-driven assessment of the sector in line with our vision of supporting timely and sustainable access to innovative medicines and treatments in Türkiye, contributing to the strengthening of the healthcare ecosystem, and increasing our country’s global competitiveness in pharmaceutical R&D.
You can read our full Türkiye Pharmaceutical Sector 2025 Report through this link.